"This retrospective cohort study found that taking GLP-1RAs was associated with a reduced overall risk of cancer, including lower risks of endometrial, ovarian, and meningioma cancers, among patients ...

While health insurance premiums have been increasing, 2026 will see the largest hike in prices since 2018, according to KFF ...

NVIDIA Corporation, Novo Nordisk A/S, Shift4 Payments Inc, Hims Hers Health Inc. Read 's Market Analysis on Investing.com ...

Wall Street started the week on a muted note, with major indices little changed as investors looked ahead to a critical speech by Fed Chair Jerome Powell and a raft of retail earnings.

Novo recently filed lawsuits against 14 small healthcare providers who sold compounded versions of its weight loss drug ...

Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company's second-quarter earnings report, alongside results from a closely watched trial of its ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

(LLY) stock hits a 52-week low as concerns over its weight-loss drug trial overshadow strong Q2 2025 results. Read more here.

Users of weight loss drugs such as Wegovy and Mounjaro, along with those who use type 2 diabetes drug Ozempic for weight loss, have reported a number of side effects (some more unpleasant than others) ...